

Media Release

10 June 2026

Results of Share Purchase Plan

Syntara Limited (ASX: SNT), a clinical-stage drug development company, announces the successful completion of its Share Purchase Plan (**SPP**), originally announced on 29 April 2026.

The SPP received support from eligible shareholders, with applications received totalling approximately \$0.84 million.

Shares were offered under the SPP at an Issue Price of A\$0.027 which represented:

- a 15.6% discount to the last closing price of Syntara's shares on the ASX on 24 April 2026 (the last trading day before the announcement of the Placement and SPP); and
- a 17.6% discount to the 5-day volume weighted average price of Syntara's shares ended 24 April 2026.

A total of 31,235,279 new fully paid ordinary shares will be issued under the SPP.

Together with the previously completed \$8.0 million placement, Syntara has now raised a total of approximately \$8.84 million before costs. Proceeds will provide a cash runway to Q3 2027 and be applied to:

- Trial readouts and licensing discussions – funding five key clinical trial readouts over CY2026 and to progress current licensing discussions across the pipeline.
- Phase 2b MF study preparation – preparatory work, including protocol finalisation, CRO selection, trial site negotiations, formulation development, and clinical trial supplies.
- Patent suite – strengthening the Company's global leading pan-LOX patent suite and add potential to exploit multiple indications.
- Offer costs – funding costs associated with the offer.

The Company wishes to thank shareholders for their continued support and participation in the SPP.

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia. www.syntaraTX.com.au.

SOURCE:

Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:
Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:
Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

JOIN THE SYNTARA MAILING LIST [HERE](#)

